Efficacy of neoadjuvant treatment with or without pertuzumab in patients with stage II and III HER2-positive breast cancer: A nationwide cohort analysis of pathologic response and 5-year survival
Anna van der Voort, Marte C. Liefaard, Mette S. van Ramshorst, Erik van Werkhoven, Joyce Sanders, Jelle Wesseling, Astrid Scholten, Marie-Jeanne Vrancken Peeters, Linda de Munck, Sabine Siesling, Gabe S. Sonke*
Dive into the research topics of 'Efficacy of neoadjuvant treatment with or without pertuzumab in patients with stage II and III HER2-positive breast cancer: A nationwide cohort analysis of pathologic response and 5-year survival'. Together they form a unique fingerprint.